real peptides FAQ

Custom peptide synthesis is standard practice for novel sequences or modified peptides. Provide the full amino-acid sequence using three-letter or one-letter codes, specify any modifications (acetylation, amidation, disulfide bonds), and indicate your required purity level and quantity. Synthesis timelines for custom peptides typically range from 3–6 weeks depending on sequence complexity and length. Our team at Real Peptides handles custom synthesis requests with the same quality protocols applied to catalog compounds. Every batch undergoes full analytical verification before shipment.

Run them as parallel treatment arms with vehicle controls, not sequentially. Cross-contamination of metabolic effects is a real risk. AOD-9604's lipolytic effects persist for 48–72 hours after the last dose, meaning a washout period between peptides would need to be at least one week. Parallel arms eliminate this issue and allow direct statistical comparison. Make sure your sample size per group accounts for the variability in each peptide's response. GHRP-2 shows higher inter-subject variability (CV ~25%) than AOD-9604 or MOTS-C (CV ~15%) due to individual differences in pituitary GH reserve.

Purchase it only if you're operating under an approved institutional research protocol with ethical oversight. Research-grade designation means the compound is manufactured for laboratory use—not human administration. No supplier can legally market SS-LUP-332 for therapeutic purposes without FDA approval, and no approval process has begun because no human safety data exists. If a vendor frames it as a supplement or wellness compound, they're violating regulatory standards and misrepresenting the compound's status.

Use MOTS-c at dosing ranges established in exercise physiology studies: 5–15 mg administered 30–60 minutes before resistance training or endurance exercise. MOTS-c's nuclear translocation is triggered by metabolic stress. Its effect amplifies when combined with ATP-depleting activity. Research shows that MOTS-c administration without concurrent exercise produces minimal mitochondrial biogenesis, whereas the combination increases PGC-1α expression by 340% compared to exercise alone. The peptide's half-life is approximately 2–3 hours, making pre-exercise timing critical for maximizing AMPK activation during the training window.

BPC-157's angiogenic effects require viable thyroid tissue to repair. If fibrosis has already replaced more than 60% of functional thyroid volume (measured by ultrasound elastography), peptide therapy will not reverse structural damage. VEGF upregulation increases microvascular density in surviving tissue but cannot regenerate destroyed follicular cells. In advanced fibrosis cases, research protocols combine BPC-157 with stem cell co-administration to provide both angiogenic scaffolding and cellular regeneration. Check serum VEGF levels at week 4. If VEGF has not increased by at least 50% from baseline, bioavailability may be compromised by improper reconstitution or storage temperature excursions.

Recheck Treg populations via flow cytometry. If CD4+CD25+FoxP3+ cells have not increased from baseline, the issue is dose inadequacy or administration frequency. Standard protocols use 1.6mg twice weekly, but some patients require 2.0mg or thrice-weekly dosing to achieve therapeutic Treg expansion. Anti-Tg antibodies should also be measured separately. Some patients show anti-TPO reduction without corresponding anti-Tg changes, indicating incomplete immune suppression. If antibodies plateau after 12 weeks despite adequate Treg expansion, add Thymosin Beta-4 to address the NF-κB-driven inflammatory component that Tα1 alone doesn't fully suppress.

Switch peptides based on mechanism, not dose. If AOD-9604 shows no hepatic fat reduction after four weeks, increasing the dose won't help. The limiting factor is likely inadequate adipose lipolysis reaching the liver, which means the model's lipid accumulation is driven by hepatocyte-intrinsic mechanisms (de novo lipogenesis or impaired fatty acid oxidation) rather than adipose delivery. In that case, MOTS-C is the logical next step because it targets hepatocyte mitochondria directly. We've seen research teams waste six months dose-escalating a mechanistically mismatched peptide when switching compounds would have clarified the pathway in two experiments.

Ignore the backticks and extract the amino-acid sequence between them. The backticks are markdown delimiters used to format the sequence as monospaced text in the original document. They're not part of the peptide's chemical structure. Cross-reference the extracted sequence against a protein database like UniProt or PDB to verify its identity. If the sequence doesn't match known entries, it may be a novel synthetic construct described in recent literature, which you can verify by searching the sequence string in PubMed or Google Scholar.

FOXO4-DRI becomes the priority intervention before other mitochondrial peptides will produce meaningful results. Senescent cells secrete IL-6, IL-8, and TNF-α that directly inhibit PGC-1α transcription. Administering MOTS-c or SS-31 in a high-senescence environment is like trying to fill a leaking bucket. FOXO4-DRI at 5 mg/kg for a 2–4 week clearance cycle eliminates the inflammatory burden first, allowing mitochondrial biogenesis and repair pathways to function without constant suppression. Researchers typically wait 4–6 weeks after senolytic treatment before introducing biogenesis-focused peptides, giving the tissue environment time to stabilize.

Administer peptides at staggered intervals to isolate individual effects. BPC-157 and TB-500 can be co-administered without interaction. Their mechanisms are independent. LL-37 should be administered separately (minimum 6-hour interval) because its antimicrobial activity can interfere with bacterial culture assays if used concurrently. Document injection sites and timing precisely to avoid confounding variables in multi-peptide protocols.

Verify reconstitution technique and peptide purity first. The single most common reason for failed replication in peptide research is reconstitution error. Injecting air into the vial during solution withdrawal creates positive pressure that draws contaminants back through the needle on subsequent draws. This degrades the peptide over multiple doses. If you're using a supplier without third-party purity verification (HPLC with UV detection at 214 nm showing ≥98% purity), that's the second most likely failure point. Published studies typically use pharmaceutical-grade peptides with batch certificates. Research-grade peptides without documentation introduce uncontrolled variables.

Request the certificate of analysis before purchasing. A legitimate research-grade supplier provides batch-specific HPLC chromatograms, mass spectrometry data, and amino-acid analysis results for every lot. If the supplier cannot or will not provide these documents, the claimed purity percentage is unverifiable and the product should be avoided. Purity claims without analytical backing are marketing statements, not quality specifications. Research reproducibility depends on knowing the exact composition of your reagents.

Use a disease model that allows multiple mechanistic targets—methionine-choline-deficient diet models work well because they produce inflammation, stellate activation, and vascular injury simultaneously. Administer peptides at equipotent doses (standardize via preliminary dose-response curves) and measure stage-specific endpoints: malondialdehyde for oxidative stress, alpha-SMA for stellate activation, and hydroxyproline for collagen deposition. Comparing peptides in models mismatched to their mechanisms produces misleading conclusions about relative efficacy.

Pinealon reduces TNF-α and IL-1β secretion from activated microglia by 25–40% in vitro, making it suitable for traumatic brain injury, stroke, or neuroinflammation models. Pair it with mitochondrial support compounds when studying oxidative stress. The Energy Mitochondria Fatigue Bundle provides complementary modulators that address both inflammatory signaling and metabolic dysfunction in neurons under stress.

The most common issue with combination therapy is overlapping immune modulation. Both peptides suppress pro-inflammatory signalling, which can transiently increase infection susceptibility if Treg populations expand too rapidly. Monitor CD4+ T-cell counts and neutrophil-to-lymphocyte ratio every 4 weeks. If NLR drops below 1.0 or total CD4+ counts fall below 400 cells/μL, reduce Tβ4 frequency to once weekly while maintaining Tα1 at standard dosing. The combination is generally well-tolerated, but patients with pre-existing immunosuppression (corticosteroid use, prior thyroidectomy with immune dysfunction) require closer monitoring.

That would be the first step toward establishing whether it's safe according to studies. Phase 1 trials would enrol 20–100 healthy volunteers, escalate doses under medical supervision, and monitor for adverse events. Results would be published in peer-reviewed journals, and only if the safety profile proved acceptable would Phase 2 and 3 efficacy trials begin. Until that process completes—typically 5–10 years for a novel compound—no credible safety claims can be made.

Switch to daily dosing in culture media rather than single-bolus application. Preliminary chronic exposure data (7–14 days) from two independent labs suggests maintained mitochondrial protection without evidence of desensitization, but the literature is sparse. If your model involves sustained oxidative stress. Chronic inflammatory conditions, prolonged metabolic dysfunction. You'll need baseline controls to confirm that SS-LUP-332 doesn't alter unstressed mitochondrial dynamics.

Discard immediately. Cloudiness indicates protein aggregation or bacterial contamination. Properly reconstituted peptides should be clear and colourless. Aggregated peptides lose bioactivity and can produce inconsistent results across experimental replicates. Use bacteriostatic water for reconstitution, refrigerate at 2–8°C, and use within 28 days. Temperature excursions above 8°C cause irreversible denaturation.

Review disease stage alignment first—if you're using TB-500 in an F0 model with no stellate cell activation, the mechanism has no target. Switch to GHK-Cu for early-stage prevention or confirm stellate cell activation markers (alpha-SMA, collagen I mRNA) before assuming peptide failure. Dose verification is the second checkpoint: peptides lose potency rapidly if stored above 8°C or reconstituted in non-sterile water. Most null results trace to storage degradation, not ineffective compounds.

They absolutely will. Peptides below 95% purity contain truncated sequences, aggregated dimers, and residual synthesis reagents that alter pharmacokinetics. A 2025 analysis in Peptide Science found that TB-500 samples below 93% purity showed 40% reduced actin-binding affinity due to N-terminal acetylation errors. Request certificate of analysis (CoA) documentation with HPLC and mass spectrometry verification for every batch. Real Peptides provides batch-specific purity reports because even 2–3% purity variance can shift dose-response curves enough to compromise replication.